Bausch & Lomb gets US and Canadian rights to Clearside's Xipere
Executive Summary
Clearside Biomedical Inc. licensed Bausch & Lomb Inc. exclusive rights to develop, manufacture, and commercialize Xipere (triamcinolone acetonide) suprachoroidal injectable suspension for macular edema and uveitis in the US and Canada.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice